IMGN - ImmunoGen EPS beats by $0.03 misses on revenue

ImmunoGen (NASDAQ:IMGN): Q2 GAAP EPS of -$0.15 beats by $0.03. Revenue of $16.95M (+12.8% Y/Y) misses by $1.97M. CEO comment: "Beyond mirvetuximab, our IMGN632, IMGC936, and IMGN151 programs are progressing as anticipated. Patient accrual continues in our IMGN632 trials in BPDCN and AML, with data from our AML cohort expected at ASH next quarter. Our dose-escalation study of IMGC936 is enrolling in multiple solid tumor types and we are on track to file the IND for IMGN151 by year-end. With a focus on execution towards key inflection points, we look forward to transforming ImmunoGen into a fully integrated oncology company with the potential for two innovative ADCs on the market in 2022." Press Release

For further details see:

ImmunoGen EPS beats by $0.03, misses on revenue